FLUORESCEIN

Non Excipient

Mwt. LogP HBD HBA PSA RB CSP3
332.0 4.0 2 4 88.0 2 0.0
CAS
2321075
UNII
TPY09G7XIR
SYNONYMS
ZINC ID(s)
Availability
Present in 47 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
CYP2C19 Cytochrome P450 2C19 Enzyme / P450
SLC22A6 Solute carrier family 22 member 6 Unclassified / Unclassified

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02389530 2015-04-01 Use of Fluorescein Dye for the Removal of Brain Tumors Phase 1/Phase 2 Not Yet Recruiting
NCT01979003 2014-09-01 A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion Phase 0 Recruiting
NCT02028325 2013-12-01 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Phase 4 Recruiting
NCT01384695 2009-06-01 A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1 Phase 0 Terminated
NCT00847522 2009-02-01 Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma Phase 1 Active, Not Recruiting
NCT01614184 2008-05-01 Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer Phase 1/Phase 2 Withdrawn
NCT00228345 2004-01-01 The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy Phase 1 Terminated

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Oral Capsule 0.01MG

More Information

Usage Over Time

Comments